Taro Pharma (TARO) Posts Inline Q4 Breakeven Loss
Tweet
Share
E-mailGet Alerts TARO Hot Sheet
Join SI Premium – FREE
Taro Pharma (NYSE: TARO) reported Q4 EPS of $0.00, versus $0.00 reported last year. Revenue for the quarter came in at $244.2 million, versus $881.79 million reported last year.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rivian reports record Q3 deliveries, beats estimates, shares rise
- Reaction roundup: Experts, analysts weigh in on September jobs report
- Freeport Q3 2026 copper output meets targets; gold sales deferred
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
